Free Proposed Pretrial Order - District Court of Delaware - Delaware

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 1 of 45

PLAINTIFFS BAYER AG, BAYER HEALTHCARE AG, AND BAYER PHARMACEUTICALS CORP.'S TRIAL EXHIBIT LIST
TRIAL EXHIBIT NO. DEPOSITION EXHIBIT NO.

DATE

DESCRIPTION Certified Copy of USPN 4,990,517, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Certified Copy of USPN 4,990,517: Certificate of Correction Certified Copy of the Prosecution History of USPN 4,990,517, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Prosecution History of USPN 4,990,517: File Cover and Examiner Search Notes Prosecution History of USPN 4,990,517: Priority Application DE 3824072.6 (7/15/1988) (German) Prosecution History of USPN 4,990,517: Priority Application DE 3824072.6 (7/15/1988) (English) Prosecution History of USPN 4,990,517: Priority Application DE 3906365.8 (3/1/1989) (German)

BATES RANGE

OBJECTION(S)1

PTX-001

2/5/1991

BL020-002557-002615

DDX 027**

PTX001-A

4/25/1995

BL020-002613

PDX 068**

PTX-002

BL020-000332-001720

DDX 096**, DDX 121**

Incomplete

PTX002-A PTX002-B PTX002-C PTX002-E 7/15/1988

BL020-000334-000335

PDX 058**

Incomplete

BL020-000714-000844

DDX 046**

7/15/1988

BL020-000896-001025

3/1/1989

BL020-000533-000713

DDX 048**

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 1 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 2 of 45

PTX002-F PTX002-G PTX002-H PTX002-I PTX002-J PTX002-K PTX002-L PTX002-M PTX002-N PTX002-O PTX002-P PTX002-Q

3/1/1989 6/30/1989 6/30/1989 6/30/1989 6/30/1989 3/28/1990 4/4/1990 4/26/1990

Prosecution History of USPN 4,990,517: Priority Application DE 3906365.8 (3/1/1989) (English) Prosecution History of USPN 4,990,517: Prosecution Transmittal Prosecution History of USPN 4,990,517: Application (USSN 375,434) Prosecution History of USPN 4,990,517: Claims as Filed Prosecution History of USPN 4,990,517: Combined Declaration and Power of Attorney Prosecution History of USPN 4,990,517: Search Results Prosecution History of USPN 4,990,517: Office Action Prosecution History of USPN 4,990,517: Examiner Interview Summary Record Prosecution History of USPN 4,990,517: USPTO Communication Providing English Translation Prosecution History of USPN 4,990,517: Declaration re Translation of German Priority Documents Prosecution History of USPN 4,990,517: Amendment with Attachment Prosecution History of USPN 4,990,517: Examiner Interview Summary Record

BL020-001027-001212 BL020-000337 BL020-000338-000528 BL020-000513-000527 BL020-000529-000530 BL020-000845-000851 BL020-000852-000859 BL020-000890 BL020-000891; BL020-000861000876 Incomplete PDX 059** DDX 074** Illegible -- Damaged DDX 047**

5/4/1990

5/10/1990

BL020-001026

7/19/1990

BL020-000892-000895; BL020000877-000879 BL020-001217

PDX 060**

8/10/1990

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 2 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 3 of 45

PTX002-R PTX002-S PTX002-U PTX002-V PTX002-W

8/27/1990

Prosecution History of USPN 4,990,517: Notice of Allowability and Examiner's Amendment Prosecution History of USPN 4,990,517: Notice of Allowance and Issue Fee Due Prosecution History of USPN 4,990,517: Issue Fee Transmittal Prosecution History of USPN 4,990,517: European Search Report Prosecution History of USPN 4,990,517: Information Disclosure Statement with PTO Form 1449 and European Search Report Prosecution History of USPN 4,990,517: PTO Form 1449 with Examiner's Initials Prosecution History of USPN 4,990,517: USPTO Communication Acknowledging Receipt of Information Disclosure Statement Prosecution History of USPN 4,990,517: Request for Certificate of Correction Prosecution History of USPN 4,990,517: Letter of Correction Prosecution History of USPN 4,990,517: Request for Certificate of Correction Prosecution History of USPN 4,990,517: Application for Patent Term Extension

BL020-001214-001216

8/27/1990 10/31/1990 11/7/1990

BL020-001213 BL020-001219-001220 BL020-001230-001234 BL020-001221; BL020-001563; BL020-001230-001234 DDX 053** DDX 136** DDX 054**, DDX 136** Incomplete

11/16/1990

PTX002-X

2/8/1991

BL020-001563

Incomplete

PTX002-Y

2/11/1991

BL020-001562

PDX 066**

Incomplete

PTX002-Z PTX002-AA PTX002-BB PTX002-CC

3/2/1992

BL020-001564-001566

Hearsay Incomplete Incomplete Improper Attachment DDX 064**, PDX 067** Relevance

3/5/1992

BL020-001567-001569

2/16/1995

BL020-001571-001575

1/28/1999

BL020-001578-001691

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 3 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 4 of 45

PTX002-DD PTX002-EE PTX002-FF PTX002-GG PTX002-HH PTX002-II

3/11/2004

Prosecution History of USPN 4,990,517: Notice of Final Determination re Patent Term Extension Prosecution History of USPN 4,990,517: Statutory Disclaimer Prosecution History of USPN 4,990,517: Certificate of Patent Term Extension Prosecution History of USPN 4,990,517: Request for Expedited Certificate of Correction Prosecution History of USPN 4,990,517: Certificate of Correction Prosecution History of USPN 4,990,517: Disclaimer Certified Copy of USPN 5,607,942, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Certified Copy of the Prosecution History of USPN 5,607,942, Petersen et al., 7-(1-Pyrrolidinyl)-3Quinolone- and Naphthyridonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Prosecution History of USPN 5,607,942: Declaration of KlausDieter Bremm

BL020-001695-001696

3/29/2004 9/16/2004

BL020-001703-001704 BL020-001698

7/7/2005 7/72005 7/14/2005

BL020-001706-001707 BL020-001708 BL020-001705

PTX-003

3/4/1997

BL020-002616-002669

PDX 051**, DDX 052**

PTX-004

BL020-001721-002479

DDX 122**

PTX004-A

12/2/1994

BL020-001937-001941

DDX 041**

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 4 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 5 of 45

PTX004-B PTX004-C PTX004-E PTX004-F PTX004-G PTX004-H PTX004-I

3/20/1995

Prosecution History of USPN 5,607,942: Request for Continuing Application Prosecution History of USPN 5,607,942: Declaration with Respect to Divisional Application Prosecution History of USPN 5,607,942: Application (USSN 737,631) Prosecution History of USPN 5,607,942: Combined Declaration and Power of Attorney Prosecution History of USPN 5,607,942: Preliminary Amendment with Attachment Prosecution History of USPN 5,607,942: Preliminary Amendment Prosecution History of USPN 5,607,942: Declaration of KlausDieter Bremm Prosecution History of USPN 5,607,942: Attachment to and References Cited in 7/20/1995 Bremm Declaration

BL020-001924-001927

3/20/1995

BL020-001918

3/20/1995

BL020-001727-001917

3/20/1995

BL020-001919-001923 BL020-001928-001930; BL020001937-001941 BL020-001931-001936 BL020-001942-001951 DDX 055**, DDX 126** DDX 058** DDX 044**

3/20/1995 5/19/1995 7/20/1995

PTX004-J

BL020-001952-001958; BL020002364-002377

DDX 044**

PTX004-K PTX004-L PTX004-M

8/1995

Prosecution History of USPN 5,607,942: Third Preliminary Amendment Prosecution History of USPN 5,607,942: Information Disclosure Statement with Attachment Prosecution History of USPN 5,607,942: Information Disclosure Statement with Attachment

BL020-002037-002040

DDX 057**

8/1995

BL020-002027-002034

DDX 056**

8/30/1995

BL020-002041-002045

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 5 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 6 of 45

PTX004-O PTX004-P PTX004-Q PTX004-R PTX004-S PTX004-U PTX-005 PTX-006 PTX-007 PTX-008 PTX-009 PTX-010

11/1/1995

Prosecution History of USPN 5,607,942: Sprung Horn Communication Attaching Appeal Decisions Prosecution History of USPN 5,607,942: Office Action Prosecution History of USPN 5,607,942: Amendment Prosecution History of USPN 5,607,942: Examiner Interview Summary Record Prosecution History of USPN 5,607,942: Notices of Allowability and Allowance Prosecution History of USPN 5,607,942: Issue Fee Transmittal Stipulation And Order Stipulation And Order Excerpt of Dr. Reddy's ANDA: Moxifloxacin Hydrochloride Tablets 400 mg CV of Professor Edward C. Taylor CV of Thomas J. Perun, Ph.D.

BL020-002046-002068

DDX 059**

Incomplete

3/8/1996 6/6/1996 7/1/1996

BL020-002069-002074 BL020-002172-002181 BL020-002171 DDX 062** Hearsay

7/18/1996

BL020-002182-002183

10/11/1996 6/13/2005 7/6/2005 12/10/2003

BL002184-002185 PDX 151** PDX 152** DRLMOX-005020-005044 BL021-000878-000927 BL021-000868-000877 BL021-000127-000234

Illegible

Relevance Hearsay Hearsay Hearsay

1/2006

CV of Dr. George G. Zhanel

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 6 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 7 of 45

PTX-011

PTX011-A PTX011-B PTX011-C PTX011-E

9/10/1990

Prosecution History of USPN 5,059,597, Petersen et al., 7-(4-Oxa or 4-Thia-2,7Diazabicyclo[3.3.0]Oct-2-en-3-yl)-3Quinolone-and-NaphthyridoneCarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Prosecution History of USPN 5,059,597: Application (USSN 580,906) Prosecution History of USPN 5,059,597: Preliminary Amendment with Attachment Prosecution History of USPN 5,059,597: Preliminary Amendment with Attachment Prosecution History of USPN 5,059,597: Information Disclosure Statement with Attachment Prosecution History of USPN 5,416,096, Petersen et al., 7-(1Pyrrolidinyl)-3-Quinolonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer)

DRLMOX 036285-036599

DRLMOX 036290-036480

9/10/1990

DRLMOX 036486-036489 DRLMOX 036492-036493; DRLMOX 036491; DRLMOX 036533-036534 DRLMOX 036501-036508 DDX 065**, DDX 085** Relevance Incomplete

10/1/1990

2/14/1991

PTX-012

DRLMOX 038215-038608

PTX012-A PTX012-B

7/30/1991 2/4/1992

Prosecution History of USPN 5,416,096: Preliminary Amendment Prosecution History of USPN 5,416,096: Office Action Prosecution History of USPN 4,840,954, Petersen et al., 6,7Disubstituted 1-Cyclopropyl-1,4Dihydro-4-Oxo-1,8-Naphthyridine-3Carboxylic Acids (Bayer)

DRLMOX 038417-038425 DRLMOX 038428-038437

PTX-013

DRLMOX 034193-035335

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 7 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 8 of 45

PTX013-A PTX013-B PTX013-C PTX013-E

12/31/1985 4/22/1986 7/22/1986 11/3/1986

Prosecution History of USPN 4,840,954: Application (USSN 815,440) Prosecution History of USPN 4,840,954: Office Action Prosecution History of USPN 4,840,954: Amendment Prosecution History of USPN 4,840,954: Office Action Prosecution History of USSN 07/298,459, Petersen et al., Quinolone- and Naphthyridone Carboxylic Acid Derivatives, Process for their Production, Antibacterial Compositions and Feed Additives Containing Them (Bayer) Prosecution History of USSN 07/298,459: Application Prosecution History of USSN 07/298,459: Examiner Interview Summary Record Prosecution History of USSN 07/298,459: Letter with Attachment Prosecution History of USSN 07/298,459: Office Action with Attachment Prosecution History of USSN 07/298,459: Declaration of KlausDieter Bremm Prosecution History of USSN 07/298,459: Amendment

DRLMOX 034198-034242 DRLMOX 034374-034382 DRLMOX 034479-034484 DRLMOX 034491-034496 PDX 100**

PTX-014

DRLMOX 040312-040972

DDX 049**

PTX014-A PTX014-B PTX014-C PTX014-E PTX014-F PTX014-G

1/18/1989 1/10/1990 1/23/1990 4/23/1990

DRLMOX 040315-040382 DRLMOX 040604 DRLMOX 040605-040607 DRLMOX 040675-040679 Hearsay

8/16/1990 8/22/1990

DRLMOX 040878-040882 DRLMOX 040868-040875

DDX 045**

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 8 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 9 of 45

PTX014-H PTX014-I PTX014-J PTX-015

11/19/1990

Prosecution History of USSN 07/298,459: Office Action with Attachment Prosecution History of USSN 07/298,459: Declaration of KlausDieter Bremm Prosecution History of USSN 07/298,459: Amendment Prosecution History of USPN 5,071,999, Schenke et al., Preparation of 2,7Diazabicyclo[3.3.0]Octanes (Bayer)

DRLMOX 040886-040890 Hearsay

1/17/1991 2/11/1991

DRLMOX 040926-040928 DRLMOX 040920-040925 DDX 140, DDX 140-A

DRLMOX 042552-042923

PTX015-A PTX015-B PTX015-C PTX-016 PTX-017

4/17/1989 4/10/1990 12/10/1991 4/16/2003 6/30/1989

Prosecution History of USPN 5,071,999: Priority Application P3912509.2 Prosecution History of USPN 5,071,999: Application USPN 5,071,999, Schenke et al., Preparation of 2,7Diazabicyclo[3.3.0]Octanes (Bayer) Minutes of New Product Development Review Meeting Prosecution History of LeA 26 108EP: Original Specification Prosecution History of LeA 26 108EP: Claims as Filed Prosecution History of LeA 26 108EP: European Patent Office Search Report Prosecution History of LeA 26 108EP: Office Action

DRLMOX 042736-042813 DRLMOX 042555-042629 DRLMOX 042870-042890 DRLMOX 016457-016478 BL001-026355-026526 PDX 016 Relevance Relevance No Translation Relevance No Translation

PTX-018

6/30/1989

BL001-026527-026540

PTX-019

11/7/1990

BL001-026627-026630 Relevance No Translation

PTX-020

11/17/1992

BL001-026622-026626

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 9 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 10 of 45

PTX-021

7/19/1993

Prosecution History of LeA 26 108EP: Letter from Bailly to the European Patent Office re: Amended Claims Prosecution History of LeA 26 108EP: Amended Patent Claims for the Contracting States: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, and SE Prosecution History of LeA 26 108EP: Amended Patent Claims for the Contracting State: ES Prosecution History of LeA 26 108EP: Amended Patent Claims for the Contracting State: GR Prosecution History of LeA 26 108EP: Office Action EP 0350733 B1, Petersen et al., 7(1-Pyrrolidinyl)-3-Quinolone- and Naphthyridone-Carboxylic-Acid Derivatives, Method for Their Preparation and for Substituted Mono- and Bi-cyclic Pyrrolidine Intermediates, and Their Antibacterial and Feed Additive Compositions (Bayer) Moxifloxacin in Practice, vol. 1

BL001-026611-026612

Relevance No Translation

PTX-022

7/19/1993

BL001-026216-026229

Relevance No Translation

PTX-023

7/19/1993

BL001-026230-026237

Relevance No Translation Relevance No Translation Relevance No Translation

PTX-024

7/19/1993

BL001-026238-026250

PTX-025

10/19/1993

BL001-026608-026610

PTX-026

8/20/1997

BL001-028133-028262

PTX-027

1999

BL007-001000-001109

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 10 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 11 of 45

PTX027-A

1999

Tillotson and Blondeau, Today's Community Respiratory Tract Infections: A Challenge Appropriate for Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 1:1-11 (1999) Petersen, et. al., The Synthesis and In Vitro and In Vivo Antibacterial Activity of Moxifloxacin (BAY 122039), A New 8-Methoxyquinolone, Moxifloxacin in Practice, Maxim Medical, 1:13-26, (1999) Felmingham et al., In Vitro Activity of Moxifloxacin (BAY 12-8039), A Novel 8-Methoxyquinolone, Comparable with Ofloxacin and Other Antibiotics, Moxifloxacin in Practice, Maxim Medical, 1:27-37 (1999) Kayser et al., In Vitro Activity of Moxifloxacin Against Invasive Pneumococcal Strains Compared with Other Antimicrobials, Moxifloxacin in Practice, Maxim Medical, 1:39-47 (1999) Verbist and Verhaegen, In Vitro Activity of Moxifloxacin (BAY 128039), A Novel 8-Methoxyquinolone, Against Gram-Positive Clinical Isolates, Moxifloxacin in Practice, Maxim Medical, 1:49-56 (1999)

BL007-001010-001020

Hearsay Relevance

PTX027-B

1999

BL007-001022-001035

Hearsay Relevance

PTX027-C

1999

BL007-001036-001046

Hearsay Relevance

PTX027-E

1999

BL007-001048-001056

Hearsay Relevance

PTX027-F

1999

BL007-001058-001065

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 11 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 12 of 45

PTX027-G

1999

Durham et al., Mechanism of Activity of Moxifloxacin Against Staphylococcus aureus In Vitro, Moxifloxacin in Practice, Maxim Medical, 1:57-62 (1999) Durham et al., Preferred Targets of Moxifloxacin in Staphylococcus aureus, Moxifloxacin in Practice, Maxim Medical, 1:63-69 (1999) Gillespie, The Activity of Moxifloxacin and Other Fluoroquinolones Against Mycobacterium tuberculosis and Other Mycobacteria, Moxifloxacin in Practice, Maxim Medical, 1:71-79 (1999) Dalhoff, In Vivo Lack of Emergence of Resistance to Moxifloxacin in Staphylococcus aureus and Streptococcus pneumoniae, Moxifloxacin in Practice, Maxim Medical, 1:81-89 (1999) Doucet-Populaire et al., In Vitro Activity of Moxifloxacin, A Novel 8Methoxyquinolone, Compared with the Activities of Macrolides, Ciprofloxacin and Levofloxacin Against Bordetella pertussis, Moxifloxacin in Practice, Maxim Medical, 1:91-97 (1999) Moxifloxacin in Practice, vol. 2

BL007-001066-001071

Hearsay Relevance

PTX027-H

1999

BL007-001072-001078

Hearsay Relevance

PTX027-I

1999

BL007-001080-001088

Hearsay Relevance

PTX027-J

1999

BL007-001090-001098

Hearsay Relevance

PTX027-K

1999

BL007-001100-001106

Hearsay Relevance

PTX-028

1999

BL007-002000-002112

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 12 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 13 of 45

PTX028-A

1999

von Keutz and Schlüter, Moxifloxacin and the Liver: Results of Preclinical Investigations, Moxifloxacin in Practice, Maxim Medical, 2:1-4 (1999) MacGowan, Pharmacodynamics of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 2:5-15 (1999) Wiedemann, In Vitro Pharmacodynamics of Moxifloxacin Against Respiratory Tract Pathogens, Moxifloxacin in Practice, Maxim Medical, 2:17-25 (1999) Jacobs and Dalhoff, Efficacy of Moxifloxacin, A New 8Methoxyquinolone, Against Group 1 and Group 2 Mycoplasma pneumoniae Strains in a Guinea-Pig Respiratory Model, Moxifloxacin in Practice, Maxim Medical, 2:27-35 (1999) Garcia-Rodriguez et al., In Vitro Activity of Moxifloxacin Against Respiratory Tract Pathogens, Moxifloxacin in Practice, Maxim Medical, 2:37-48 (1999) Debbia et al., Activity of Moxifloxacin Against Antibiotic-Resistant Streptococcus pyogenes, Moxifloxacin in Practice, Maxim Medical, 2:49-60 (1999)

BL007-002010-002013

Hearsay Relevance

PTX028-B

1999

BL007-002014-002024

Hearsay Relevance

PTX028-C

1999

BL007-002026-002034

Hearsay Relevance

PTX028-E

1999

BL007-002036-002044

Hearsay Relevance

PTX028-F

1999

BL007-002046-002057

Hearsay Relevance

PTX028-G

1999

BL007-002058-002069

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 13 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 14 of 45

PTX028-H

1999

M'Zali et al., Differential Selection of Quinolone Resistance by New Quinolone in Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus, Moxifloxacin in Practice, Maxim Medical, 2:61-69 (1999) Nichterlein et al., The Activity of Moxifloxacin, A New 8Methoxyquinolone, Against Strains of Salmonellae and Listeria monocytogenes In Vitro, In Mouse Infections and In Infected Tissue Cells, Moxifloxacin in Practice, Maxim Medical, 2:71-82 (1999) Vohr et al., An Investigation into the Phototoxic Potential of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 2:83-90 (1999) Tillotson and Blondeau, StructureActivity-Function Evaluation of Fluoroquinolones, Moxifloxacin in Practice, 2:91-101 (1999) Moxifloxacin in Practice, vol. 3. Read, Clinical Overview: Moxifloxacin in Community Respiratory Tract Infections, Moxifloxacin in Practice, Maxim Medical, 3:1-14 (2000)

BL007-002070-002078

Hearsay Relevance

PTX028-I

1999

BL007-002080-002091

Hearsay Relevance

PTX028-J

1999

BL007-002092-002099

Hearsay Relevance

PTX028-K

1999

BL007-002100-002110

Hearsay Relevance Hearsay Relevance

PTX-029

2000

BL007-003000-003089

PTX029-A

2000

BL007-003010-003023

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 14 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 15 of 45

PTX029-B

2000

Stass et al., The Effect of Food on the Oral Bioavailability of Moxifloxacin in Healthy Male Volunteers, Moxifloxacin in Practice, Maxim Medical, 3:15-23 (2000) von Keutz, Moxifloxacin: Effects on Joints and Tendons in Experimental Animals, Moxifloxacin in Practice, Maxim Medical, 3:25-31 (2000) Morrissey and Hunter, The Importance of the Ability of an Antimicrobial Agent to Kill the Pathogen, Moxifloxacin in Practice, Maxim Medical, 3:33-48 (2000) Felmingham et al., The In Vitro Activity of Moxifloxacin Against 817 Isolates of Streptococcus pneumoniae Collected from 27 Centres Throughout Great Britain and Ireland During the 1997 - 1998 Cold Season, Moxifloxacin in Practice, Maxim Medical, 3:49-56 (2000) King et al., The Comparative In Vitro Activity of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 3:57-63 (2000)

BL007-003024-003032

Hearsay Relevance

PTX029-C

2000

BL007-003034-003040

Hearsay Relevance

PTX029-E

2000

BL007-003042-003057

Hearsay Relevance

PTX029-F

2000

BL007-003058-003065

Hearsay Relevance

PTX029-G

2000

BL007-003066-003072

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 15 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 16 of 45

PTX029-H

2000

Gemmell, Some Features of the Interaction Between Moxifloxacin, Granulocyte-Colony Stimulating Factor and Neutrophils in Relation to the Intracellular Survival of Salmonella typhimurium, Moxifloxacin in Practice, Maxim Medical, 3:65-72 (2000) Herrington et al., Factors Affecting the In Vitro Activity of Moxifloxacin, Moxifloxacin in Practice, Maxim Medical, 3:73-79 (2000) Mitscher et al., Structure-Activity Relationships of the Newer Quinolone Antibacterial Agents, Quinolones, (Fernandes ed.), Prous, 3-20 (1989) Sanchez et al., Quinolone Antibacterial Agents. Synthesis and Structure-Activity Relationships of 8Substituted Quinolie-3-Carboxylic Acids and 1,8-Naphthyidine-3Carboxylic Acids, J. Med. Chem., 31:983-991 (1988) Sanchez et al., Quinolone Antibacterial Agents. Synthesis and Structure-Activity Relationships of 8Substituted Quinolie-3-Carboxylic Acids and 1,8-Naphthyidine-3Carboxylic Acids, J. Med. Chem., 31:983-991 (1988) (date stamped copy)

BL007-003074-003081

Hearsay Relevance

PTX029-I

2000

BL007-003082-003088

Hearsay Relevance

PTX-032

1989

PDX 032

Hearsay Relevance

PTX-033

1988

PDX 033

Hearsay Relevance

PTX033-D

5/8/1988

BL021-000799-000812

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 16 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 17 of 45

PTX-034

1986

Domagala et al., New StructureActivity Relationships of the Quinolone Antibacterials Using the Target Enzyme. The Development and Application of a DNA Gyrase Assay, J. Med. Chem., 29:394-404 (1986) USPN 4,284,629, Grohe et al., Process for the Preparation of 4Pyridone-3-Carboxylic Acids and/or Derivatives Thereof (Bayer) USPN 4,341,784, Matsumoto et al., Naphthyridine Derivatives (Dainippon) EP Application 0106489 A2, Culbertson et al., Antibacterial Agents (Warner-Lambert) EP Application 0106489 B1, Culbertson et al., Antibacterial Agents (Warner-Lambert) USPN 4,638,067, Culberson et al., Antibacterial Agents (WarnerLambert) USPN 4,777,175, Culbertson et al., Antibacterial Agents (WarnerLambert) EP Application 0181521 A1, Tone et al., Antimicrobial 1-Subtitued Phenyl-4-Oxoquinolone-3Carboxylic Acid Compounds (Otsuka)

PDX 034

Hearsay Relevance

PTX-035

8/18/1981

BL020-000321-000331

Hearsay Relevance

PTX-036

7/27/1982

DRLMOX 030245-030254

PDX 036

PTX-037

4/25/1984

DRLMOX 027092-027216

PDX 037

PTX-038

4/25/1984

BL021-001191-001246

PTX-039

1/20/1987

SH-000001-009319-009355

PTX-040

10/11/1988

BL021-000086-000121

PTX-041

5/21/1986

PDX 041

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 17 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 18 of 45

PTX-042

1988

Excerpt from Abstracts of the Annual Meeting of the American Society for Microbiology 1988, abstracts A-13 through A-17 re: PD 117,596 and PD 127,391 Cohen et al., In Vitro Activity of PD 117596 and PD 127391, New Quinolone Antimicrobic Agents, Annual Meeting of the American Society for Microbiology 1988, Abstract A17 Excerpt from Abstracts of the Annual Meeting of the American Society for Microbiology 1988, cover and table of contents (date stamped copy) Smith et al., In Vitro Activities of PD 117,596 and Reference Antibiotics Against 448 Clinical Bacterial Strains, Antimicrob. Agents Chemother., 32(9):1450-1455 (1988) King et al., The In Vitro Activity of PD 127,391, A New Quinolone, J. Antimicrob. Chemother., 22:135-141 (1988) EP Application 0195316 A1, Irikura et al., Quinolonecarboxylic Acid Derivatives (Kyorin) EP Application 0241206 A2, Iwata et al., Quinoline-3-Carboxylic Acid Derivatives (Sankyo) BL021-000016-000058

PDX 042

Hearsay Relevance Incomplete

PTX042-A

1988

Hearsay Relevance Incomplete

PTX042-D

4/12/1988

BL021-000859-000862

Hearsay Relevance Incomplete

PTX-043

9/1988

PDX 043

Hearsay Relevance

PTX-044

1988

PDX 044

Hearsay Relevance

PTX-045

3/6/1986

PTX-046

10/14/1987

DRLMOX 008890-009078

PDX 046, DDX 028**

Typo in certification

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 18 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 19 of 45

PTX-047

1985

Program and Abstracts of the 25th ICAAC: Abstract 565 Synthesis and Antibacterial Activity of AT-3765, a New Pyridonecarboxylic Acid Antibacterial Agent 14th International Congress of Chemotherapy: Abstract P-35-41, AT-3295, A New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure-Activity Relationships Domagala et al., 7-Substituted 5Amino-1-Cyclopropyl-6,8-Difluoro1,4-Dihydro-4-Oxo-3Quinoinecarboxylic Acids: Synthesis and Biological Activity of a New Class of Quinolone Antibacterials, J. Med. Chem., 31:503-506 (1988) Domagala et al., 7-Substituted 5Amino-1-Cyclopropyl-6,8-Difluoro1,4-Dihydro-4-Oxo-3Quinoinecarboxylic Acids: Synthesis and Biological Activity of a New Class of Quinolone Antibacterials, J. Med. Chem., 31:503-506 (1988) (date stamped copy) Minutes Meeting from Project: Substances for Chemical Therapy Minutes from the AKF "Antibacterial Therapy" Meeting on 9/23/1987

PDX 047

Hearsay Relevance

PTX-048

6/1985

PDX 048

PTX-050

1988

PDX 050

Hearsay Relevance

PTX050-D

3/10/1988

BL021-000813-000822

Hearsay Relevance

PTX-051

8/1/1985

BL018-142240-142244

Relevance Incomplete No Translation Relevance No Translation

PTX-052

10/22/1987

BL002-096559-096562

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 19 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 20 of 45
Relevance No Translation Relevance No Translation Hearsay Relevance Incomplete No Translation Hearsay Hearsay Lack of Specific Description General Objection Pending Inspection of Documents Hearsay Lack of Specific Description General Objection Pending Inspecting of Documents

PTX-053

9/20/1993

Minutes from the AK-F "Quinolones" Meeting Quinolonecarboxylic Acids: Number of Patents (Graph) Quinolonecarboxylic Acids: Number of Patents (Graph)

BL004-034177-034199

PTX-054

1/1994

BL005-020346-020346

PTX-055

1/20/1994

BL005-020279-020279

PTX-056

Petersen Patent Abstract Card Collection Box 1

PTX-057

Petersen Patent Abstract Card Collection Box 2

PTX-058

10/14/1987

Patent Abstract Card for EP 241206, New 7-Heterocyclic-1,4-Dihydro-4Oxoquinolone-3 Carboxylic Acid Cpds- Useful as Antibacterial Agents with Activity Against Resistant Strains (Sankyo) USPN 4,649,144, Matsumoto et al., Antibacterial 7-(3-Amino-1Pyrrolidinyl)-1-Cyclopropyl-6-Fluoro1,4-Dihydro-4-Oxo-1,8Naphthyridine-3-Carboxylic Acid Derivatives (Dainippon) Manual of Patent Examining Procedure: Foreword (5th ed.)

BL005-038418-038420

Hearsay

PTX-059

3/10/1987

BL021-000059-000085

PTX-060

8/1983

DRLMOX 042166-70

Illegible Incomplete

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 20 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 21 of 45

PTX-061

5/19/1988

Manual of Patent Examining Procedure: Chapter 800 (5th ed., 8th rev.) Manual of Patent Examining Procedure: Chapter 2239 (5th ed., 12th rev.)

DRLMOX 041664-041692

PDX 061 Incomplete

PTX-062

BL021-000928-000929

PTX-063

10/2005

Manual of Patent Examining Procedure: Foreword (8th ed., 4th rev.) Manual of Patent Examining Procedure: Chapter 800 (8th ed., 4th rev.) Prosecution History of USPN 4,990,517: Table of Contents

BL021-001073-001079 BL021-001073-001078; BL021001083-001154 DRLMOX 041013 SH_000001-000025 BL021-000235-000244 DRLMOX 035842-035848 DRLMOX 041633-041663 PDX 069 PDX 070 PDX 065

Relevance

PTX-064 PTX-065 PTX-066 PTX-067 PTX-069 PTX-070

10/2005

Relevance

11/12/1990 8/17/2005 2/25/1991 5/1986

Prosecution History of USPN 4,990,517: Letter from Bailly and Danner to Sprung Horn Expert Report of Lowell S. Young with paragraph 20 redacted Prosecution History of USPN 5,059,597: Examiner's Action Manual of Patent Examining Procedure: Chapter 2000 (5th ed., 3rd rev.) DRL's Objections and Responses to Plaintiffs' First Set of Interrogatories (1-8)

Relevance

PTX-071

2/11/2005

Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 21 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 22 of 45

PTX-072

4/7/2005

PTX-073

6/20/2005

Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.'s Responses to Plaintiffs Bayer AG, Bayer Healthcare AG and Bayer Pharmaceuticals Corporation's Second Request for Admission (Nos. 12-26) Dr. Reddy's Response to Bayer's Contention Interrogatories 37-38 and 42-44 Dr. Reddy's First Supplemental Response to Bayer's Interrogatories (Nos. 25, 28, 31, 39-41 and 46) Notice of Dr. Reddy's Pursuant to Fed. R. Civ. P. 30(b)(6) BE Application 887574, Surugadai, et al., Dérivés de l'acide quinoléinecarboxylique et procédé pour leur préparation (Kyorin) UK Patent Application GB 2093018A, Irkura, et al., 6,8Difluoro-Quinoline Carboxylic Acid Derivatives (Kyorin) SciFinder Scholar Entries Press Release: TB Alliance and Bayer Launch Historic Global Drug Trials for Tuberculosis Report: Synthesis of Substituted Piperazines- New Basic Heterocycles for Gyrase Inhibitor Substitution in Pos. 7 BL021-001260-001284 PDX 001

Relevance

Relevance Relevance Relevance Hearsay Relevance No Translation Late Production Hearsay Relevance Late Production Hearsay Relevance Late Production Hearsay Relevance Late Production Hearsay Relevance No Translation

PTX-074 PTX-075

8/3/2005 5/11/2005

PTX-076

6/15/1981

PTX-077

8/25/1982

BL021-001247-001259

PTX-078

BL021-001354-001405

PTX-079

10/18/2005

BL021-001406-001409

PTX-080

11/13/1987

BL004-037074-037099

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 22 of 45

Case 1:04-cv-00179-SLR
PTX-081 PTX-101 12/2/1987

Document 108-7

Filed 03/03/2006

Page 23 of 45

Bottle of Avelox® 400 mg Tablets Compound Card for PEW 6412B Excerpt from Laboratory Notebook re: SES 695 Excerpt from Laboratory Notebook re: SES 721 USPN 4,571,396, Hutt et al., Antibacterial Agents (WarnerLambert) EP Application 0159174 A2, Hutt et al., Substituted Naphthyridine-, Quinolone- and BenzoxazineCarboxylic Acids as Antibacterial Agents and Processes for Their Production (Warner-Lambert) Compound Card for SEW 2554 BL005-033591 PDX 101 Hearsay Relevance No Translation

PTX-102 PTX-103 PTX-105

11/3/1987 12/10/1987 2/18/1986

BL009-009402 BL009-009432

PDX 102 PDX 103 PDX 105 Hearsay Relevance

PTX-106

10/23/1985

BL021-001539-001602

Hearsay Relevance

PTX-140

BL002-008043

PDX 140

Hearsay Relevance No Translation Hearsay Relevance No Translation Hearsay Relevance No Translation Hearsay Relevance No Translation

PTX-141

4/6/1989

Compound Card for SEW 2532

BL002-008048

PDX 141

PTX-142

5/14/1993

Annotated Compound Card for PEW 7645B

BL005-032755

PDX 142

PTX142-A

5/14/1993

Compound Card for PEW 7645B

BL005-032755

PDX 142**

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 23 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 24 of 45

PTX-160

Collection of Bayer data

BL002-016090-016092; BL002015364; BL002-039374-039377; BL004-0036010 BL002-053026; BL002-016090016092; BL002-053419-053420; BL002-053431-053436 BL002-016190; BL005-032769; BL002-028585-028588; BL002028611; BL005-016145; BL018033385-033404; BL002-022251; BL002-015411; BL002-022002022003; BL002-022023; BL018036136; BL002-015376-015377; BL002-023467-023470; BL002023485; BL002-024301-024303; BL002-038381-038382; BL002038331-038332; BL002-038399038400; BL018-072235-072243; BL018-034030-034032; BL002038137-038139; BL002-074197; BL018-033228-033237; BL002015492; BL002-022416; BL002022429; BL005-033530; BL005017276; BL002-027301-027303; BL002-027325; BL005-032230; BL005-032018; BL011-015123015141; BL002-015256; BL005034006; BL002-093024-093026; BL018-111095; BL005-033734; BL018-032451-032481; BL002015469; BL002-022310-022311

Hearsay Relevance No Translation Hearsay Relevance No Translation

PTX-161

Collection of Bayer data

PTX-162

Collection of Bayer data

PDX 162

Hearsay Relevance Incomplete No Translation

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 24 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 25 of 45
Hearsay Relevance Incomplete No Translation

PTX-163

Collection of Bayer data

PTX-164

Collection of Bayer data

PTX-165

Collection of Bayer data

BL002-014006; BL005-016118; BL002-074178; BL005-016101; BL005-016088; BL002-015489; BL005-017427; BL002-015241015243 BL002-001000-017113; BL002074142-075006; BL004-036003036043; BL004-036351-036373; BL005-013016-013017; BL005013308; BL005-016000-017520; BL005-032000-034372; BL005051757-051758; BL018-013009013017; BL018-016265-016296; BL018-035000-037283; BL018038303-038313; BL018-039031039563; BL018-086000-086402; BL018-089000-089243; BL018090084-090107; BL018-090145090214; BL018-092081-092217; BL018-104000-104081; BL018108004-108013; BL018-109081109100; BL018-110000-111461 BL008-012351-012365; BL002023023-023026; BL002-035382035384; BL018-085021; BL008012124-012159; BL002-046505; BL002-024331-024332; BL002094120-094121; BL002-094077; BL002-035343-035345; BL002014006

Hearsay Relevance Incomplete No Translation

Hearsay Relevance Incomplete No Translation

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 25 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 26 of 45

PTX-166

Collection of Bayer data

BL005-032230; BL002-028585028588; BL002-029458-029460; BL002-029461-029483; BL002029484; BL002-042018-042022; BL002-043082-043086; BL002043209-043212; BL002-051341051355; BL002-051356-051369; BL002-051387-051400; BL002053255-053267; BL002-053343053361; BL002-053437-053443; BL002-053460-053464; BL002053466-053470; BL002-054072054074; BL002-055188-055190; BL002-056135-056141; BL002062105-062108; BL002-093066093069; BL002-094080; BL005015098-015099; BL005-040367040368; BL005-044265-044284; BL005-053426-053427; BL008017261-017267; BL008-018319018340 BL018-036159; BL018-051253; BL018-036149; BL018-052053; BL018-036108

Hearsay Relevance Incomplete No Translation

PTX-167

Collection of Bayer data

Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation

PTX-168

Collection of Bayer data

BL018-036287; BL018-039245; BL018-035251

PTX-169

Collection of Bayer data

BL004-005282; BL004-005694; BL004-005713-005714

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 26 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 27 of 45

PTX-170

Compound Card for PEW 6348

BL005-051757

PTX-171

Collection of Bayer data

BL002-009295; BL002-014009; BL002-014014-014015; BL002014021-014031

Hearsay Relevance Incomplete No Translation Illegible Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation Hearsay Relevance No Translation Hearsay Relevance No Translation

PTX-172

Collection of Bayer data

BL002-016201; BL002-028585-88; BL002-028611; BL002-015505; BL002-022432-33; BL002-022457

PTX-173

Bayer data In vitro antibacterial activity of the new quinolone BAY Y3118 against clinical isolates (draft), with cover letter Comparative In Vitro Activity of BAY Y3118, A New 4-Quinolone, and Ciprofloxacin Against Mycobacterium tuberculosis and M. avium complex (draft)

BL002-107015-107016

PTX-174

1/26/1994

BL002-130322-130337

PTX-175

10/26/1993

BL002-129263-129270

Hearsay Relevance

PTX-176

Collection of Bayer data

BL005-033319; BL005-033675; BL005-015105-015107; BL002133112; BL018-028370-028373; BL018-029131-029133; BL002038444-038445; BL018-121025121043; BL002-039135-039139; BL002-114248

Hearsay Relevance Incomplete No Translation

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 27 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 28 of 45
Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation Hearsay Relevance Incomplete No Translation

PTX-177

10/6/1992

BAY Y3118 IND Excerpt

BC004-001072; BC004-001166001170

DDX 021**

PTX-178

10/6/1992

BAY Y3118 IND Excerpt

BC004-001072; BC004-001134-41

DDX 021**

PTX-179

Collection of Bayer data

BL018-036084; BL018-033260033270; BL002-008043; BL002022262-022263; BL002-022279 BL002-015171; BL002-024388024390; BL002-024411; BL002016145; BL002-028419-028422; BL002-028451; BL018-036102; BL018-033260-033270; BL002008046; BL002-022262-022263; BL002-022279

PTX-180

Collection of Bayer data

Hearsay Relevance Incomplete No Translation

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 28 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 29 of 45

PTX-181

Collection of Bayer data

BL005-033780; BL018-028326028332; BL005-033726; BL018028199-028204; BL005-033575; BL018-078305-078307; BL005033529; BL018-070211-070220; BL002-038005; BL002-038262038264; BL018-034030-034032; BL005-033539; BL002-039685039687; BL005-033533; BL018078084-078086; BL005-033483; BL018-070086-070088; BL005033535; BL018-078174-078177; BL005-033515; BL018-078047078051; BL005-033490; BL018070179-070181; BL005-033486; BL018-070028-070029; BL005033449; BL018-070053-070054; BL005-033474; BL018-070074070075; BL005-033441; BL002038002-038004; BL005-033409; BL002-038490-038492; BL005033344; BL002-038259-038261; BL005-033343; BL002-038256038258; BL002-038017; BL005033327; BL002-039593; BL005033323; BL002-039610-039613; BL005-033232; BL002-040598040599; BL005-033319; BL002133112; BL002-039477-BL002039479; BL005-033315; BL002039435-039437; BL005-033310; BL002-040673-040674; BL005033293; BL002-039423-039425;

PDX 181

Hearsay Relevance Incomplete No Translation

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 29 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 30 of 45

BL005-033287; BL002-039303039305; BL005-033285; BL002040665-040667; BL005-033278; BL002-039235-039237; BL005033270; BL002-039131-039133; BL005-033252; BL002-094077; BL005-033254; BL002-039070039073; BL005-033247; BL002040624-040625; BL005-033034; BL002-041312-041314; BL005033033; BL002-041308-041310; BL005-032753; BL002-133113; BL005-032740; BL002-043384; BL005-032718; BL002-043356; BL005-032711; BL002-043317; BL005-032709; BL002-043322; BL005-032672; BL002-094082; BL002-012063; BL018-070078070079 PTX181-A BL005-033033; BL002-041308041310 BL002-015376-015377; BL002038137-038139; BL018-028370028373; BL018-029131029133;BL002-038444-038445; BL018-121025-121043; BL002038412-038413; BL002-041540041543; BL018-089174-089184 Hearsay Relevance Incomplete No Translation

Collection of Bayer data

PTX-182

Collection of Bayer data

Hearsay Relevance Incomplete No Translation

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 30 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 31 of 45

PTX-201

8/2003

Allen et al., Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an in vitro Pharmacodynamic Model, Antimicrob. Agents Chemother., 47(8):2606-2614 (2003) Andrews et al., Concentrations of Levofloxacin (HR 355) in the Respiratory Tract Following a Single Oral Dose in Patients Undergoing Fibre-Optic Bronchoscopy, J. Antimicrob. Chemother., 40:573-577 (1997) Ashby et al., An Investigation of the Hydrophobicity of the Quinolones, Correspondence Section, Journal of Antimicrob. Chemother., 16:805-810 (1985) Berger, Synthesis of Some Conformationally Restricted Analogues of Fentanyl, J. Med. Chem., 20:600-602 (1977) Bermudez et al. Activity of Moxifloxacin by Itself and in Combination with Ethambutol Rifabutin, and Azithromycin in vitro and in vivo Against Mycobacterium avium, Antimicrob. Agents Chemother., 45:217-222 (2001)

BL021-000576-000584

Hearsay Relevance Late Production

PTX-202

1997

BL021-000965-000969

Hearsay Relevance

PTX-203

1985

BL021-000245-000248

Hearsay Relevance

PTX-204

1977

BL021-000698-000700

Hearsay Relevance

PTX-205

1/2001

BL021-000471-000476

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 31 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 32 of 45

PTX-206

3/1996

Bermudez et al., Activities of BAY Y3118, Levofloxacin and Ofloxacin Alone or in Combination with Ethambutol against Mycobacterium avium Complex in vitro, in Human Macrophages and in Beige Mice, Antimicrob. Agents Chemother., 40:546-551 (1996) Bermudez et al., SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease, Antimicrob. Agents Chemother., 48:3556-3558 (2004) Birkofer & Feldmann, Über Bicyclische Dilactame, Justus Liebigs, Ann. der Chemie, 677:154157 (1964) Blondeau et al., Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae, Antimicrob. Agents Chemother., 45:433-438 (2001) Borne et al., Conformationally Restrained Fentanyl Analogues. 2. Synthesis and Analgetic Evaluation of Perhydro-1,6-naphthyridin-2ones, J. Med. Chem., 27:1271-1275 (1984)

BL021-000701-000706

Hearsay Relevance

PTX-207

9/2004

BL021-000477-000479

Hearsay Relevance

PTX-208

1964

SH_000001-004018-004019

PTX-209

2/2001

BL021-000377-000382

Hearsay Relevance

PTX-210

1984

BL021-000707-000711

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 32 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 33 of 45

PTX-211

2002

Boswell et al., Comparison of the In Vitro Activities of Several New Fluoroquinolones Against Respiratory Pathogens and Their Abilities to Select Fluoroquinolone Resistance, J. Antimicrob. Chemother., 50:495-502 (2002) Chapman et al., Routes of Quinolone Permeation in Escherichia coli, Antimicrob. Agents Chemother., 32:438-442 (1988) Chen et al., Decreased Susceptibility of Streptococcus pneumonia to Fluoroquinolones in Canada, N. Engl. J. Med., 341:233239 (1999) Cook et al., Concentrations of OPC17116, A New Fluoroquinolone Antibacterial, in Serum and Lung Compartments, J. Antimicrob. Chemother., 35:317-326 (1995) Cornett and Wentland, Quinolone Antibacterial Agents, Ann. Rpts. Med. Chem., 21(ch. 14):139-148 (1986) Davidson et al., Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia, N. Engl. J. Med., 346:747-750 (2002)

BL021-000585-000592

Hearsay Relevance

PTX-212

4/14/1988

BL021-000823-000828

Hearsay Relevance

PTX-213

7/22/1999

BL021-000712-000718

Hearsay Relevance

PTX-214

1995

BL021-000970-000979

Hearsay Relevance

PTX-215

1986

BL021-001410-001421

Hearsay Relevance

PTX-216

3/7/2002

BL021-000719-000722

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 33 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 34 of 45

PTX-217

6/2001

Doern et al., Antimicrobial Resistance Among Clinical Isolates of Streptococcus pneumoniae in the United States During 1999-2000, Including a Comparison of Resistance Rates Since 1994-1995, Antimicrob. Agents Chemother., 45:1721-1729 (2001) Domagala et al., 1-Ethyl-7-[3[(ethylamino)methyl]-1-pyrrolidinyl]6,8-difluoro-1,4-dihydro-4-oxo-3quinoline-carboxylic Acid. New Quinolone Antibacterial with Potent Gram-Positive Activity, J. Med. Chem., 29:445-448 (1986) Evans et al., Methods for Drug Discovery : Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists, J. Med. Chem., 31:2235-2246 (1988) Fernandes and Chu, Quinolone Antibacterial Agents, Ann. Rpts. Med. Chem., 23 (ch. 14):133-140 (1988) Fernandes and Chu, Quinolones, Ann. Rpts. Med. Chem., 22 (ch. 12):117-126 (1987) Fernandes, Mode of Action, and In Vitro and In Vivo Activities of the Fluoroquinolones, J. Clin. Pharmacol., 28:156-168 (1988)

BL021-000541-000549

Hearsay Relevance

PTX-218

1986

BL021-000391-000394

Hearsay Relevance

PTX-219

1988

BL021-000723-000734

Hearsay Relevance

PTX-220

9/13/1988

BL021-000843-000858

Hearsay Relevance

PTX-221

1987

BL021-001422-001433

Hearsay Relevance

PTX-222

3/16/1988

BL021-000829-000842

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 34 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 35 of 45

PTX-223

4/2004

Florea et al. Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations Against Streptococcus pneumoniae, Antimicrob. Agents Chemother., 48:1215-1221 (2004) Fuller and Low, A Review of Streptococcus pneumoniae Infection Treatment Failures Associated with Fluoroquinolone Resistance, Clin. Infect. Dis., 41:118-121 (2005) Gatifloxacin - The Drug Class of Quinolones is Growing, Zeitschrift für Chemotherapie, 22:36 (2001) Gatifloxacin - The Drug Class of Quinolones is Growing, Zeitschrift für Chemotherapie, 22:36 (2001) (Translation) Gemifloxacin (Factive), The Medical Letter, 46(1192):78-79 (2004) Gosling et al., The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis, Am. J. Respir. Crit. Care Med., 168:13421345 (2003) Gotfried et al., Steady-State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Health Adult Subjects, Chest, 119:1114-1122 (2001)

BL021-000746-000752

Hearsay Relevance

PTX-224

7/2005

BL021-000735-000738

Hearsay Relevance

PTX-225

2001

BL020-000201-000203

Hearsay Relevance No Translation Hearsay Relevance No Translation Hearsay Relevance

PTX-226

2001

BL020-000204-000207

PTX-227

9/27/2004

BL021-000786-000788

PTX-228

2003

BL021-000602-000605

Hearsay Relevance

PTX-229

4/2001

BL021-000944-000952

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 35 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 36 of 45

PTX-230

1987

Heifets et al., Determination of MICs of Conventional and Experimental Drugs in Liquid Medium by the Radiometric Method Against Mycobacterium Avium Complex, Drugs. Expl. Clin. Res., 13(9):529538 (1987) Hirai et al., Differences in Susceptibility to Quinolones of Outer Membrane Mutants of Salmonella typhimurium and E. coli, Antimicrob. Agents and Chemother., 29:535-538 (1986) Kennedy, Managing the Drug Discovery/Development Interface, Drug Discovery Today 2:10, 436444 (1997) Klein et al., Uber die Synthese und pharmakologische Wirkung cyclischer Analoga des Fentanyls, Arch. Pharmaz., 308:910-916 (1975) Kreis et al., A Comparison of Moxifloxacin and Azithromycin in the Treatment of Acute Exacerbations of Chronic Bronchitis, JCOM, 7(12):3337 (2000) Létourneau et al., Gatifloxacin (TequinTM): Hypoglycemia and Hyperglycemia, Can Adv React News. Health Can., 13:1-2 (2003)

BL021-000662-000671

Hearsay Relevance

PTX-231

3/1986

BL021-000254-000257

Hearsay Relevance

PTX-232

10/10/1997

BL021-001182-001190

Hearsay Relevance

PTX-233

1975

BL021-000739-000745

Hearsay Relevance No Translation

PTX-234

12/2000

BL021-000753-000757

Hearsay Relevance

PTX-235

7/2003

BL021-000536-000540

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 36 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 37 of 45

PTX-236

2001

Lister and Sanders, Pharmacodynamics of Moxifloxacin, Levofloxacin and Sparfloxacin Against Streptococcus pneumoniae, J. Antimicrob. Chemother., 47(6):811-818 (2001) Man et al., Fluoroquinolone Phototoxicity: A Comparison of Moxifloxacin and Lomefloxacin in Normal Volunteers, J. Antimicrob. Chemother., 43 (supp. B):77-82 (1999) Mouton et al., Standardization of Pharmacokinetic/Pharmacodynamic (PK/PD) Terminology for AntiInfective Drugs: an Update, J. of Antimicro. Chemother. 55:601-607 (2005) Nagai et al., Single- and Multi-Step Resistance Selection Study of Gemifloxacin Compared with Trovafloxacin, Ciprofloxacin, Gatifloxacin and Moxifloxacin in Streptococcus pneumoniae, J. Antimicrob. Chemother., 48(3):365374 (2001) Nuermberger et al., Moxifloxacincontaining Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis, Am. J. Respir. Crit. Care. Med. 169:421-426 (2004)

BL021-000611-000618

Hearsay Relevance

PTX-237

1999

BL021-000554-000559

Hearsay Relevance

PTX-238

2005

BL021-000930-000936

Hearsay Relevance

PTX-239

2001

BL021-000619-000628

Hearsay Relevance

PTX-240

2004

BL021-000953-000958

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 37 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 38 of 45

PTX-241

2005

Pier and Ramphal, P. aeruginosa, Principles and Practice of Infectious Diseases, 6th ed. Chapter 216 (2005) Pletz et al., Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study, Antimicrob Agents Chemother 48:780-782 (2004) Rubinstein, History of Quinolones and Their Side Effects, Chemother., 47(suppl. 3):3-8 (2001) Soman et al., Concentrations of Moxifloxacin in Serum and Pulmonary Compartments Following a Single 400mg Oral Dose in Patients Undergoing Fibre-Optic Bronchoscopy, J. Antimicrob. Chemother., 44(6):835-838 (1999) Wentland and Cornett, Quinolone Antibacterial Agents, Ann. Rpts. Med. Chem., 20(ch. 15):145-154 (1985) Wilson et al., Short-term and Longterm Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis, Chest, 125(3):953-964 (2004)

BL021-001434-001465

Hearsay Relevance

PTX-242

3/2004

BL021-000635-000637

Hearsay Relevance

PTX-243

2001

BL021-000406-000411

Hearsay Relevance

PTX-244

1999

BL021-000572-000575

Hearsay Relevance

PTX-245

1985

BL021-001466-001479

Hearsay Relevance

PTX-246

3/2004

BL021-000412-000423

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 38 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 39 of 45

PTX-247

1996

Wise and Honeybourne, A Review of the Penetration of Sparfloxacin into the Lower Respiratory Tract and Sinuses, J. Antimicrob. Chemother., 37(suppl. A):57-63 (1996) Wise, Maximizing Efficacy and Reducing the Emergence of Resistance, J. Antimicrob. Chemother., 51(suppl. S1):37-42 (2003) Woodcock et al., In Vitro Activity of BAY 12-8039, a New Fluoroquinolone, Antimicrobial Agents and Chemother. 41(1):101106 (1997) Wright, Cefsulodin, Drug Intel. and Clin. Pharm. 20:845-849 (1986) Zhanel and Noreddin, Pharmacokinetics and Pharmacodynamics of the New Fluoroquinolones: Focus on Respiratory Infections, Curr. Opin. Pharmacol., 1:459-463 (2001) Zhanel et al., Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002, Antimicrob. Agents Chemother., 47(6):1867-1874 (2003)

BL021-000937-000943

Hearsay Relevance

PTX-248

2003

BL021-000959-000964

Hearsay Relevance

PTX-249

1/1997

BL021-000789-000794

Hearsay Relevance

PTX-250

11/1986

BL021-000863-000867

Hearsay Relevance

PTX-251

2001

BL021-000676-000680

Hearsay Relevance

PTX-252

6/2003

BL021-000648-000655

Hearsay Relevance

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 39 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 40 of 45

PTX-253

2001

Zhanel et al., In Vitro Pharmacodynamic Modeling Simulating Free Serum Concentrations of Fluoroquinolones Against Multidrug-resistant Streptococcus pneumoniae, J. Antimicrob. Chemother., 47:435-440 (2001) Zhanel et al., Pharmacodynamic Activity of Fluoroquinolones Against Ciprofloxacin-Resistant Streptococcus pneumoniae, J. Antimicrob. Chemother., 49:807-812 (2002) Zhanel, Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection, Cur. Infect. Dis. Rpts., 3:29-34 (2001) Drawing of ciprofloxacin by Dr. Remmel EP Application 0132845 A2, Matsumoto et al., Novel 1,8Naphthyridine Derivatives, and Process for Preparation Thereof (Dainippon) Bayer AG Organisationplan Status Report 1985- AKF "Antibacterial Therapy" Status Report 1986- AKF "Antibacterial Therapy"

BL021-000686-000691

Hearsay Relevance

PTX-254

2002

BL021-000656-000661

Hearsay Relevance

PTX-255

2001

BL021-000692-000697

Hearsay Relevance

PTX-257

PDX 257

Hearsay Relevance

PTX-328

2/13/1985

BL021-001285-001353

No Translation

PTX1011 PTX1013 PTX1014

1/1/1988 1/21/1986 1/26/1987

BL010-005257-005493 BL002-100310-100343 BL002-100266-100309

DDX 011 DDX 013 DDX 014

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 40 of 45

Case 1:04-cv-00179-SLR
PTX1015 PTX1016 PTX1017 PTX1018 PTX1019 PTX1020 PTX1022

Document 108-7

Filed 03/03/2006

Page 41 of 45

1/26/1988 1/16/1989 1/18/1990 1/16/1991 1/9/1992 1/5/1994

Status Report 1987- AKF "Antibacterial Therapy" Status Report 1988- AKF "Antibacterial Therapy" Status Report 1989- AKF "Antibacterial Therapy" Status Report - AK Research "Antibacterial Therapy" 1990 Status Report - AK Research "Antibacterial Therapy" 1991 Status Report: AK Research "Quinolones" 1993 ICAAC 1992 Poster #642, Petersen et al., BAY Y3118, A Novel 4Quinolone: Synthesis and in vitro Activity ICAAC 1992 Poster #642, Petersen et al., BAY Y3118, A Novel 4Quinolone: Synthesis and in vitro Activity (with enlargements) USPN 4,666,920, Grohe et al., Antibacterial 1,7-Diamino-1,4Dihydro-4-Oxo-3Quinolonecarboxylic Acids (Bayer) ICAAC 1992 Poster #643, Thurberg et al., In Vitro Activity of BAY Y3118, a New Quinolone

BL002-100216-100265 BL002-100063-100132 BL002-100133-100169 BL002-096340-096380 BL002-096239-096283 BL002-096010-096054

DDX 015 DDX 016 DDX 017 DDX 018 DDX 019 DDX 020 Relevance Incomplete

1992

BL009-036178

DDX 022

Illegible

PTX1022-A

1992

BL009-036178

DDX 022-A

Illegible

PTX1023

5/19/1987

DRLMOX 040973-040982

DDX 023

PTX1025

1992

SH000001-005240-005242

DDX 025

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 41 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 42 of 45

PTX1026

12/22/1992

USPN 5,173,484, Petersen et al., Quinolone- and Naphthyridone Carboxylic Acid Derivatives, Process for Their Production, Antibacterial Compositions, and Feed Additives Containing Them (Bayer) Compound Card for PEW 6902 Compound Card for PEW 6957 Compound Card for PEW 6873B Minutes Emergency Team Meeting BAY Y3118, 3/93 on 3/17/1993 Report from Bremm summarizing Daiichi DU-6859 Status Report: AK Research "Quinolones" 1994 PC 10/94 Meeting Minutes Report: BAY 11-6371 (tosylate) and BAY 12-8039 (hydrochloride): Results of Microbiological Tests Prosecution History of USSN 08/026,906: Combined Declaration and Power of Attorney Prosecution History of USSN 08/026,906: Original Specification Prosecution History of USSN 08/026,906: Declaration by Dr. Klaus-Dieter Bremm

DRLMOX 030539-030564

DDX 026

PTX1030 PTX1031 PTX1032 PTX1034 PTX1035 PTX1036 PTX1037 PTX1038 PTX1039 PTX1040 PTX1041

7/26/1990 10/4/1990 5/18/1990 1/25/1993 7/13/1994 1/16/1995 11/4/1994 3/10/1995

BL002-015256 BL002-015187 BL005-017418 BL005-047236-047247 BL002-097136-097142 BL002-097006-097043 BL002-134176-134177 BL002-134026-134081

DDX 030 DDX 031 DDX 032 DDX 034 DDX 035 DDX 036 DDX 037 DDX 038 Hearsay Hearsay

4/23/1993 3/5/1993 12/2/1994

BL001-014381-014382 BL001-014002-014135 DRLMOX 038825-038829

DDX 039 DDX 040 DDX 041

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 42 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 43 of 45

PTX1069

11/8/1994

Prosecution History of USSN 08/026,906: Letter from Briscoe (Sprung Horn) to Pross (Patent Providers) re request to deliver an Amendment and Petition for Extension of Time Prosecution History of USSN 08/026,906: Second Amendment under Rule 116 Prosecution History of USSN 08/026,906: Amendment under Rule 111 Prosecution History of USSN 08/026,906: Amendment Under Rule 116 Prosecution History of USSN 08/026,906: Notice of Appeal From the Primary Examiner to the Board of Patent Appeals and Interferences Report: 1-Cyclopropyl-8-MethoxyQuinolonecarboxylic Acid Petersen's Laboratory Notebook for PEW 6731 - PEW 6875 Petersen's Laboratory Notebook for PEW 6876 - PEW 7000 Petersen, The Evolution of Quinolones: From Nalidixic Acid to the Third-Generation Quinolones, Pharmazie in unserer Zeit, 30(5):376-381 (2001) Petersen et al., Synthesis and in vitro Activity of BAY 12-8039, A New 8-Methoxyquinolone, Poster F001

SH_000001-004600

DDX 069

PTX1070 PTX1071 PTX1072

12/15/1994

SH_000001-005134-005137

DDX 070

2/16/1994

SH_000001-005176-005187

DDX 071

11/8/1994

SH_000001-005153-005163

DDX 072

PTX1073 PTX1075 PTX1078 PTX1079

11/10/1994

SH_000001-005149-005150

DDX 073 No Translation

6/2/1993

BL005-012468-012500 BL008-011000-011521 BL008-012000-012469

DDX 075 DDX 078 DDX 079

PTX1080

2001

DRLMOX 030951-030956

DDX 080

PTX1084

BL005-019300

DDX 084

Illegible

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 43 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 44 of 45

PTX1091

10/22/1991

USPN 5,059,597, Petersen et al., 7(4-Oxa or 4-Thia-2,7Diazabicyclo[3.3.0]Oct-2-en-3-yl)-3Quinolone-and-NaphthyridoneCarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) USPN 5,416,096, Petersen et al., 7(1-Pyrrolidinyl)-3Quinolonecarboxylic Acid Derivatives as Antibacterial Agents and Feed Additives (Bayer) Patent File LeA 26 108-USA-3CIP Dainippon Abstracts (AT-3295) Recent Advances in Chemotherapy, Proceedings of the 14th International Congress of Chemotherapy (Kyoto, 1985) Nakamura et al., In vitro, Antibacterial Activity of AT-3295, a New Pyridonecarboxylic Acid Derivative, Proceedings of the 14th International Congress of Chemotherapy, Kyoto (1985) Minami et al., In vivo Effect of AT3295 Against Experimental Infections, Proceedings of the 14th International Congress of Chemotherapy, Kyoto (1985)

BL001-011005-011111

DDX 091

PTX1092 PTX1093 PTX1115

5/16/1995

BL001-013005-013058

DDX 092

BL001-014000-014393

DDX 093

1985

DRLMOX 041901-041909

DDX 115

PTX1115-A

1985

DRLMOX 041904-041905

DDX 115**

PTX1115-B

1985

DRLMOX 041906-041907

DDX 115**

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 44 of 45

Case 1:04-cv-00179-SLR

Document 108-7

Filed 03/03/2006

Page 45 of 45

PTX1115-C

1985

Matsumoto et al., AT-3295, a New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure-Activity Relationships, Proceedings of the 14th International Congress of Chemotherapy, Kyoto (1985) Petersen, Quinolone Antibiotics: The Development of Moxifloxacin (Galley Proof)

DRLMOX 041908-041909

DDX 115**

PTX1135 PTX1135-A 2006

BL020-000223-000278 BL021-001480-001538

DDX 135 DDX 135**

Petersen, Quinolone Antibiotics: The Development of Moxifloxacin Albrecht, Development of Antibacterial Agents of Nalidixic Acid Type, Progress in Drug Res., vol. 21, (Jucker ed.), Birkhauser, 9-104 (1977) USPN 4,665,079, Culberson et al., Antibacterial Agents (WarnerLambert) Draft Stipulation and Order

PTX1158

8/1977

BL005-030407-030458

DDX 158

Hearsay Relevance Late Production

PTX1165 PTX1170

5/12/1987

DRLMOX 026952-026988

DDX 165 DDX 170 Not Evidence Relevance

As used in the foregoing objections, "Relevance," "No Translation" and "Illegible" refer to Federal Rules of Evidence 401, 402, ands 403; "Hearsay" refers to Federal Rules of Evidence 801, 802, and 805; "Incomplete" refers to Federal Rules of Evidence 106, 401, 402, and 403. By setting forth these objections to the documents on Bayer's Trial Exhibit list, Reddy does not concede that the descriptions of the documents on Bayer's list are necessarily accurate.
1

Reddy reserves its right to object further to documents on or added to this list on any basis that depends upon how a document is introduced, for what purpose a document is introduced, and what portion of a document is introduced.

** DENOTES DIFFERENT VERSION OF THE SAME OR A SIMILAR DOCUMENT WAS A DEPOSITION EXHIBIT

Page 45 of 45